HCMSG The Hepatitis C Mentor & Support Group, Inc.
Search
  • Home
  • About Us
    • Our Mission
    • Board of Directors
  • Resources
    • Hep C Facts & Stats
    • Patient Assistance Programs
    • Research and Publications
    • Reading
    • Links
  • Programs/Training
    • The Hepatitis C Education and Support Group Assistance Program
    • The Circle Model >
      • THE CIRCLE Registration
    • Healthcare Provider Training
  • Newsletter
  • Blog
  • Support Us
  • Contact Us

Hep C Treatment Yields Normal Life Span for Infected

11/13/2014

0 Comments

 
By Michelle Fay Cortez  Nov 11, 2014 4:08 PM ET

People with advanced hepatitis C infections live just as long as their healthy peers who don’t have the liver virus, provided they get treatment to eliminate the disease, researchers said.

The report, published today in the Journal of the American Medical Association, suggests that even patients who are already showing signs of liver damage from the virus can fully recover. Patients who weren’t cured had markedly shorter lives, the study from the Netherlands found.

The publication comes amid controversy over the cost of a new generation of medicines, which have better cure rates and fewer side effects than past treatments yet that also come with high prices. Gilead Sciences Inc.’s Harvoni has shown cure rates of more than 90 percent and costs more than $1,000 a pill. Gilead and other drugmakers say the expense is justified by reducing the virus’s long-term complications.

The findings “should motivate a broad spectrum of healthcare workers to be alert for hepatitis C infection,” said Adriann van der Meer, the lead author from Erasmus University Medical Center in Rotterdam. “Even in case of cirrhosis you are not too late to do something about this disease.”

About 3.2 million Americans have hepatitis C, according to the U.S. Centers for Disease Control and Prevention. The virus can be symptomless for years before eventually damaging the liver, which can cause the organ’s failure or cancer.

No More Injections The study involving 530 patients began before medicines like Gilead’s Harvoni were approved. It relied instead on older combination drugs that included interferon, an expensive injection that can cause severe flu-like symptoms. The new medicines don’t need the injections to get a cure, called a sustained virologic responseand marked by the absence of virus in the blood six months after treatment is complete.

The 10-year survival rate was 91 percent for patients who experienced a sustained virologic response, about the same as expected among people the same age and gender in the general population, the researchers said. Only 74 percent of those who still showed signed of infection lived for another decade.

The results should be confirmed when interferon-free therapies are more widely used since they may be able to cure patients with the most advanced disease, van der Meer said in an e-mailed response to questions. Those patients may be too sick to return their life expectancy to normal, he said.

The study was funded by the Foundation for Liver and Gastrointestinal Research in the Netherlands. The seven authors all reported receiving compensation for lecturing, consulting or other activities conducted on behalf of drugmakers working on hepatitis C treatments, including Gilead.

To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at mcortez@bloomberg.net 

To contact the editors responsible for this story: Crayton Harrison attharrison5@bloomberg.net Drew Armstrong, Stephen West

http://www.bloomberg.com/news/2014-11-11/hep-c-treatment-yields-normal-life-span-for-infected.html

0 Comments



Leave a Reply.

    Archives

    November 2019
    October 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013
    December 2012
    November 2012
    October 2012
    September 2012
    August 2012
    July 2012
    June 2012
    May 2012
    April 2012
    March 2012
    February 2012
    January 2012
    December 2011
    November 2011
    October 2011
    September 2011
    August 2011
    July 2011
    June 2011
    May 2011

    Categories

    All

    RSS Feed

Privacy Policy